Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song, Jun Zhu, Kaiyang Ding et al.|The Lancet Oncology|2023

Cited by 55